Navigation Links
Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
Date:10/12/2010

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy patients with good prognostic factors.

Those whose cancers relapse or do not respond to upfront therapy currently have few second-line treatment options and palliative care is the option in the majority of cases.

Dr Andrea Necchi from Fondazione IRCCS Istituto Nazionale dei Tumori of Milan and colleagues have begun a Phase-II trial using pazopanib in this setting. Pazopanib is a selective inhibitor of several signaling pathways that contribute to tumor growth and the development of new cancer-related blood vessels (angiogenesis).

So far, the researchers have enrolled 18 patients of a total of 41 planned. Each participant had metastatic urothelial cancer that had already failed to respond to at least one prior chemotherapy regimen. This means that investigators treated many patients who had already failed more than two chemotherapy regimens. Patients were administered 800mg of the drug once daily until their disease progressed or they experienced unacceptable toxicity.

"Thus far, four patients have seen their tumors shrink but, much more interestingly, the great majority of the patients --twelve out of eighteen-- saw their metastases begin to die," Dr Necchi said.

The death of these metastatic tumors, described formally as 'necrotic evolution', was observed by the researchers on monthly computed tomography and positron emission tomography scans.

"Considering this drug partly acts to prevent tumors recruiting the blood supplies they need to live and grow, necrotic evolution of metastases is not completely surprising," Dr Necchi said. "But this is the first time we have seen this phenomenon in so many cases of urothelial cancer. The challenge is to translate this kind of activity into a survival advantage."

"Of course we are only at the first step of this Phase-II trial and caution is needed when interpreting results," Dr Necchi said. "A longer follow-up time and greater sample size are needed before we can declare the study a success. However, for the first time in this disease we are generating interest among investigators and, particularly, of pharmaceutical industry."

The current trial is independent of the pharmaceutical industry, Dr Necchi noted. The sponsor is Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. "The study shows that it is possible in Europe to promote independent research that focuses attention on challenging problematic matters, such as salvage therapy in urothelial cancer."

"These preliminary results underline the value of angiogenesis as a target in bladder cancer," commented Dr Joaquim Bellmunt, Section Chief, Solid Tumor Oncology at Hospital del Mar in Barcelona, Spain. "They add to results other groups have published recently using similar drugs to treat bladder cancer."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
2. New Tool Shows Promise for Early Lung Cancer Screening
3. Womens race and class impact contraception recommendations, UCSF study shows
4. Bloodstream infection surveillance inconsistent between institutions, U-M study shows
5. Study shows faith-based interventions can encourage exercise in older African-American women
6. Study shows patient-specific vaccines for metastatic melanoma may induce durable complete regression
7. Unique gastroenterology procedure developed in adults shows promise in pediatrics
8. Novel Rheumatoid Arthritis Drug Shows Early Promise
9. Experimental Drug Shows Promise for Bone Marrow Disorder
10. Report shows federal poverty guidelines leave states seniors destitute
11. Study shows tranquil scenes have positive impact on brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume ... Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. ... can pick and choose from hand-crafted trend-setting designs with smooth animations that will ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Theravance Biopharma, Inc. (NASDAQ: ... announced the presentation of positive clinical data for ... kinase (JAK) inhibitor designed to be intestinally restricted, ... European Crohn,s and Colitis Organization (ECCO). In a ... its completed Phase 1 study of single-ascending and ...
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits ... effects allegedly associated with use of the atypical antipsychotic ... Philadelphia Court of Common Pleas, where the ... tort program. According to a notice posted on the ... convene a meeting on March 9, 2017 at 11:00 ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology: